Chromocell Therapeutics Corporation (CHRO)
After hours:
| Previous Close | 1.9900 |
| Open | 1.7900 |
| Bid | 1.2800 x 900 |
| Ask | 2.0000 x 1200 |
| Day's Range | 1.2200 - 1.8700 |
| 52 Week Range | 1.2100 - 6.0000 |
| Volume | |
| Avg. Volume | 33,479 |
| Market Cap | 7.2M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireChromocell Issues Letter to Stockholders from Chief Executive Officer
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its Chief Executive Officer, Frank Knuettel, has issued the following letter to stockholders: Dear Fellow Stockholders, With my inaugural letter to stockholders, I am pleased to provide an update on our recent initial public offering (“IPO”), share our mission, o
- GlobeNewswire
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
New Program Targets Estimated $2.5 Billion Eye Pain MarketFREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler. The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications. Commo
- GlobeNewswire
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its interim CEO Frank Knuettel, has been appointed as the Company’s permanent CEO. “I’m grateful to our board of directors and Chromocell’s investors for their support over the past seven months and for the confidence they have shown in my ability to lead the Company,”
